Tag: AMB-FUBINACA
Name that Drug: A stimulating psychoactive perspective
DATIA focus features a regular column titled, “Name that Drug” where interesting facts about a mystery drug are described.
Synthetic drugs: Common questions
Dr. Kim Samano presented information about synthetic cannabinoids ("K2/Spice") and designer stimulants known as “bath salts” in our recent webinar.
Synthetic drugs: What you need to know
Our webinar will provide an overview of synthetic drugs, review trends in usage and patterns and discuss the challenges for a workplace program.
CNN reports on synthetic drugs
Media reports tragic accounts of taking synthetic drugs. Quest Diagnostics monitors these ever-changing substances to add to our drug test panels.
Dangers of synthetic cannabinoids
Synthetic cannabinoids change frequently and Quest works to stay current with drug-use patterns by adding compounds to our drug test panels.
New to drug testing: Synthetic marijuana
In our ongoing quest to help keep workplaces drug-free, we now offer a synthetic cannabinoids panel to test for commonly detected compounds.
Quest Diagnostics tests for synthetic cannabinoids
Quest Diagnostics now offers a synthetic cannabinoids panel testing for AM-2201, JWH-018, JWH-019, JWH-073, JWH-250, UR-144 and XLR11 compounds.
Quest Diagnostics now tests for synthetic stimulants (bath salts)
Quest Diagnostics offers a comprehensive suite of drug testing products and services which now includes testing for synthetic stimulants (bath salts).
Synthetic cannabinoid user profile
The first study to obtain a detailed profile of users of synthetic cannabinoid was published in the May 20 issue of the CESAR report.
Synthetic cannabinoids linked to acute kidney injury
Acute kidney injury following exposure to synthetic cannabinoids, in sixteen cases, has been identified in six states.
